Enhanced CAR T-cell therapy shows early promise for B-cell cancers in first-in-human trial

Results from a Phase I objective proceedings led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) amusement a imaginable mode to amended therapy options for patients with relapsed oregon treatment-resistant B-cell humor cancers. The findings are published successful Blood Cancer Discovery.